Answers are grounded in this paper and cite their sources.
Background Reliable biomarkers to distinguish adrenocortical carcinoma (ACC) from benign adrenal adenoma (AD) and to stratify postoperative risk remain an unmet clinical need. PCDHGC3 , a clustered protocadherin previously linked to aggressiveness in endocrine malignancies, has not been investigated in ACC. Results Here, we analyzed PCDHGC3 promoter methylation in 60 surgically resected adrenal tumors (48 ACCs and 12 ADs) to assess its diagnostic and prognostic value. Tumors were classified according to PCDHGC3 promoter methylation status using an optimized threshold. Hypermethylation was detected in 87.5% of ACCs and in none of the ADs (p < 0.0001) achieving 100% specificity and 87.5% specificity. Methylation status was independent of age, sex, tumour size, ENSAT stage, Ki-67 index and Weiss score. Among ENSAT I–III ACCs, PCDHGC3 promoter methylation predicted shorter event-free survival (median 11.4 vs 31.0 months, p = 0.027), while Ki-67 > 20% was associated with worse overall survival. These findings were externally validated in the TCGA ACC cohort, where PCDHGC3 hypermethylation and low mRNA expression similarly correlated with poor prognosis. In SW13 ACC cells, PCDHGC3 was found epigenetically silenced through promoter methylation and decitabine treatment restored its expression. Functional assays revealed that PCDHGC3 re-expression induced G1-phase arrest supporting a tumor suppressor role. Conclusions PCDHGC3 promoter methylation is a highly specific biomarker of malignancy in adrenocortical tumours and identifies a biologically aggressive ACC subset, supporting its potential clinical utility as a rule-in diagnostic and risk-stratification tool.
No takes yet. Share an insight, caveat, or question.
Cubiella et al. (2026) studied this question.
Synapse has enriched 10 related papers. Consider them for comparative context: